FOUSE JACQUALYN A 4

What Happened Jacqualyn A. Fouse, a director of Madrigal Pharmaceuticals (MDGL), received equity awards on 2026-06-17: 454 restricted stock units (RSUs) and a derivative award for 766 shares (granted at $0.00). The combined awards cover 1,220 underlying shares; no cash was paid for these awards. These are grants (compensation/award), not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-17; Form filed 2026-06-18 (timely).
• Awards: 454 RSUs (acquired at $0.00) and a derivative award for 766 shares (acquired at $0.00).
• Vesting: Both awards vest on the earlier of (i) June 17, 2027 or (ii) the issuer’s 2027 annual meeting of stockholders, provided Ms. Fouse remains in service on that date (see footnotes F1 and F2).
• The derivative award is an option-style grant that vests as described (footnote F2); it does not indicate immediate exercise or sale.
• Shares owned after the transaction are not specified in the provided filing excerpt.
• Filing appears timely (reported the day after the transaction).

Context These grants are typical director compensation intended to align long-term interests with shareholders; they are awards rather than purchases or sales and will only convert to owned shares if and when they vest (and, for the option, if exercised). For investors, award grants are informational about compensation and retention but do not directly reflect current buying or selling by the insider.